Abstract
In the past decade, impressive strides have been made in the diagnosis and management of atherosclerotic, aneurysmal, and thromboembolic diseases, thanks in large part to the explosive growth in both vascular biology and clinical vascular medicine. We review what we consider to be the top 12 advances in this field: the discovery of nitric oxide, the metabolic syndrome, new thrombophilic disorders, therapeutic angiogenesis, endoluminal treatment of chronic venous disease, and a variety of drugs, including sildenafil, cilostazol, low-molecular-weight heparins, oral direct thrombin inhibitors, clopidogrel, statins, and angiotensin-converting enzyme inhibitors and angiotensin-receptor blocking agents.
MeSH terms
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Cilostazol
-
Clopidogrel
-
Factor V / genetics
-
Heparin, Low-Molecular-Weight / therapeutic use
-
Hot Temperature / therapeutic use
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Metabolic Syndrome / therapy
-
Mutation
-
Nitric Oxide / therapeutic use
-
Phosphodiesterase Inhibitors / therapeutic use
-
Piperazines / therapeutic use
-
Platelet Aggregation Inhibitors / therapeutic use
-
Purines
-
Sildenafil Citrate
-
Sulfones
-
Tetrazoles / therapeutic use
-
Thrombin
-
Ticlopidine / analogs & derivatives*
-
Ticlopidine / therapeutic use
-
Vascular Diseases / diagnosis*
-
Vascular Diseases / drug therapy
-
Vascular Diseases / surgery
-
Vascular Diseases / therapy*
-
Vascular Surgical Procedures*
Substances
-
Angiotensin-Converting Enzyme Inhibitors
-
Heparin, Low-Molecular-Weight
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Phosphodiesterase Inhibitors
-
Piperazines
-
Platelet Aggregation Inhibitors
-
Purines
-
Sulfones
-
Tetrazoles
-
factor V Leiden
-
Nitric Oxide
-
Factor V
-
Clopidogrel
-
Sildenafil Citrate
-
Thrombin
-
Cilostazol
-
Ticlopidine